Plozasiran (Redemplo): how it works, status and trials
Approved Nov 2025 (FCS)siRNA injectionLowering triglycerides
Plozasiran (Redemplo) is an injection given every three months that cuts the messenger RNA for apoC-III, so triglyceride-rich particles clear faster. It was approved in November 2025 for familial chylomicronemia syndrome (FCS).
In technical terms: RISC-mediated cleavage of APOC3 mRNA.
The highlighted badge marks where Plozasiran (Redemplo) acts. Open the full map or compare every therapy.
At a glance
- Acts on
- APOC3 mRNA · liver
- How it is given
- GalNAc-siRNA · SC every 3 months
- What the main trial found
- TG −80% (median, FCS; PALISADE)
- Status (curated October 25, 2026)
- Approved Nov 2025 (FCS)
Where it fits in the body
Triglyceride-rich lipoproteins
VLDL from the liver and chylomicrons from the gut carry triglyceride. Lipoprotein lipase (LPL) on capillary walls breaks it down. ANGPTL3 and apoC-III act as brakes on this process. Removing either brake (11–15) lowers triglycerides, and ANGPTL3 blockade also lowers LDL-C without needing LDL receptors, which matters in homozygous FH.
RNA and gene-editing therapies
These drugs act before a protein is made. siRNA and antisense drugs are attached to GalNAc, which hepatocytes take up, and they destroy one specific mRNA. A dose lasts weeks to months. Gene editors (10, 13) make a permanent single-dose change to the DNA and are in early trials.
Trials and registry status
From ClinicalTrials.gov, PubMed and openFDA, refreshed monthly. Last run October 27, 2026.
Plozasiran (Redemplo) from Arrowhead
Stage: US approved 2025-11-18. 2 active of 11 registered trials. 3 new papers in the last 31 days.
- MUIR-3 (NCT06347133): completed, primary completion 2026-06-01
Evidence
- PALISADE (PubMed 39225259)
Common questions
How does Plozasiran (Redemplo) work?
Plozasiran (Redemplo) is an injection given every three months that cuts the messenger RNA for apoC-III, so triglyceride-rich particles clear faster. It was approved in November 2025 for familial chylomicronemia syndrome (FCS). In technical terms: RISC-mediated cleavage of APOC3 mRNA. It acts on APOC3 mRNA · liver.
How much does Plozasiran (Redemplo) lower cholesterol or other lipids?
TG −80% (median, FCS; PALISADE). Individual results differ, and a clinician can say what to expect for one person.
Is Plozasiran (Redemplo) approved, and what is the status?
Approved Nov 2025 (FCS) (curated October 25, 2026). Registry stage as of October 27, 2026: Plozasiran, US approved 2025-11-18.
How is Plozasiran (Redemplo) taken?
GalNAc-siRNA · SC every 3 months.
Read more
Related therapies
- Evinacumab (Evkeeza): Approved 2021 (HoFH)
- Olezarsen (Tryngolza) and volanesorsen: Olezarsen approved 2024; volanesorsen EU only
- Fibrates (fenofibrate): Approved (generic)
- Icosapent ethyl (Vascepa): Approved
Educational, not medical advice. Mechanism and status text curated October 25, 2026; registry data refreshed October 27, 2026. Registries can lag company announcements. Effects are placebo-adjusted results from the main published trial, not head-to-head comparisons. Investigational agents are available only in clinical trials. Preval Health does not practice medicine; licensed clinicians in a partner network provide care. If you have chest pain or signs of a stroke, call 911.